Small changes in eGFR with TDF preexposure prophylaxis

Small changes in eGFR with TDF preexposure prophylaxis

(HealthDay)—For HIV-1-uninfected members of serodiscordant couples, tenofovir disoproxil fumarate (TDF) used as preexposure prophylaxis (PrEP) is associated with a small decrease in estimated glomerular filtration rate (eGFR), according to a study published online Dec. 22 in JAMA Internal Medicine.

Kenneth K. Mugwanya, M.B.Ch.B., from the University of Washington in Seattle, and colleagues examined whether TDF-based PrEP causes eGFR decline in HIV-1-uninfected adults. The authors conducted a per-protocol safety analysis of changes in eGFR in a randomized, placebo-controlled trial of daily oral TDF and emtricitabine (FTC)-TDF PrEP among heterosexual HIV-1-uninfected members of serodiscordant couples. Of the 4,640 participants (63 percent men), 1,548 were assigned to once-daily TDF, 1,545 to FTC-TDF, and 1,547 to placebo.

During a median follow-up of 18 months, the researchers found average decreases in eGFR attributable to PrEP versus placebo of −1.23 mL/min/1.73 m² (P = 0.004) for TDF and −1.59 mL/min/1.73 m² (P < 0.001) for FTC-TDF. By one month after randomization the difference in mean eGFR appeared between PrEP and ; it was stable through 12 months and decreased thereafter. The proportion of people with a confirmed decrease of eGFR of 25 percent or greater from baseline to 12 or 24 months was not significantly different in the TDF or FTC-TDF groups versus the .

"Our data support the safety of TDF-based PrEP in heterosexual populations as part of a comprehensive HIV-1 prevention package," the authors write.

The study medication was donated by Gilead Sciences.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Journal information: JAMA Internal Medicine

Copyright © 2014 HealthDay. All rights reserved.

Citation: Small changes in eGFR with TDF preexposure prophylaxis (2014, December 23) retrieved 14 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Protection against HSV-2 is added benefit of tenofovir


Feedback to editors